

.....  
(Original Signature of Member)

117TH CONGRESS  
2D SESSION

# H. R. 7192

To provide for the establishment of a panel on the real world impact of  
diagnostic medical devices, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

Ms. SCHRIER introduced the following bill; which was referred to the  
Committee on \_\_\_\_\_

---

## A BILL

To provide for the establishment of a panel on the real  
world impact of diagnostic medical devices, and for other  
purposes.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Diagnostic Device Ad-  
5       visory Committee Act”.

6       **SEC. 2. REAL WORLD IMPACT OF MEDICAL DEVICES PANEL.**

7       (a) IN GENERAL.—The Secretary of Health and  
8       Human Services (in this section referred to as the “Sec-

1   retary”) shall, without regard to the provisions of title 5,  
2   United States Code, governing appointments in the com-  
3   petitive service, and without regard to the provisions of  
4   chapter 51 and subchapter III of chapter 53 of such title  
5   relating to classification and General Schedule pay rates,  
6   amend the charter of the Medical Devices Advisory Com-  
7   mittee (or successor advisory committee) to establish a  
8   panel of experts on diagnostic medical device products for  
9   the purpose of providing advice to the Secretary in connec-  
10   tion with the real world impact of the clearance, classifica-  
11   tion, approval, and authorization of devices, including di-  
12   agnostic devices, under sections 510(k), 513(f), 515, and  
13   564 of the Federal Food, Drug, and Cosmetic Act (21  
14   U.S.C. 360(k), 360c(f), 360e, and 360bbb–3) to be known  
15   as the Real World Impact of Medical Devices Panel (re-  
16   ferred to in this section as the “Panel”).

17       (b) APPLICATION OF FACCA.—The Federal Advisory  
18   Committee Act shall apply to the Panel.

19       (c) MEMBERSHIP.—

20           (1) IN GENERAL.—The Panel shall consist of  
21   15 members, including the Chair.

22           (2) REPRESENTATION.—11 members of the  
23   Panel shall be voting members. Of the remaining 4  
24   members of the Panel—

1 (A) 1 shall be a representative of consumer  
2 interests;

3 (B) 1 shall be a representative of the inter-  
4 ests of the device manufacturing industry; and

5 (C) 2 shall be public health or population  
6 health-specific representatives.

7 (3) TERM.—The members of the Panel speci-  
8 fied in subparagraphs (A) through (C) of paragraph  
9 (2) shall be selected by the Secretary and shall be  
10 invited to serve for rotating terms of such duration  
11 as specified by the Secretary, except that any mem-  
12 ber appointed to fill a vacancy for an unexpired term  
13 shall be appointed for the remainder of that term.

14 (d) DUTIES.—The Panel shall provide to the Sec-  
15 retary—

16 (1) advice and recommendations on the real  
17 world impact of the clearance, classification, ap-  
18 proval, and authorization of devices, including diag-  
19 nostic devices, under sections 510(k), 513(f), 515,  
20 and 564 of the Federal Food, Drug, and Cosmetic  
21 Act (21 U.S.C. 360(k), 360c(f), 360e, and 360bbb–  
22 3), including the impact of such devices on rural,  
23 underserved, or minority populations; and

24 (2) register comments about the negative and  
25 positive impacts of such devices on the United

1 States population, the risk assessment posed by the  
2 use of such devices, and the need such devices would  
3 fill.

4 (e) CONSIDERATION OF RECOMMENDATIONS.—The  
5 Secretary, acting through the Commissioner of Food and  
6 Drugs, and any other applicable official shall, in making  
7 any final decisions, or amending existing decisions with  
8 respect to the clearance, classification, approval, and au-  
9 thorization of devices, including diagnostic devices, under  
10 sections 510(k), 513(f), 515, and 564 of the Federal  
11 Food, Drug, and Cosmetic Act (21 U.S.C. 360(k),  
12 360e(f), 360e, and 360bbb–3), take comments received  
13 from the Panel under advisement.

14 (f) MEETINGS.—

15 (1) FREQUENCY.—The Panel shall hold at least  
16 1 meeting each year, at the call of the Chair.

17 (2) RECORDINGS AVAILABLE.—Recordings of  
18 the meetings of the Panel shall be available on the  
19 public website of the Food and Drug Administration.